ABVX:EPA
Abivax SA
82,50 €
arrow_downward
-0,96%(-0,80) 1D
12 қар., 17:38:08 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
83,50 €
High
84,30 €
Low
81,50 €
Mkt. cap
7,31 млрд
Avg. vol.
110,88 м.
Volume
109,15 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
83,50 €
High
84,30 €
Low
81,50 €
Mkt. cap
7,31 млрд
Avg. vol.
110,88 м.
Volume
109,15 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
Yahoo Finance
·
32 минут бұрын
Dow, S&P 500, Nasdaq Futures Edge Higher As Markets Attempt To Recover From Nvidia Rout: SLS, MSFT, CADL, MSTR In Focus
Eurasia Business News
·
4 сағат бұрын
Stock Market Today, November 12, 2026: Dow, S&P 500 and Nasdaq Fall After Jensen Huang Resigns
ChartMill
·
8 сағат бұрын
Most Active S&P 500 Stocks: KDP, Ford, AT&T Lead Today's Session
Traders Union
·
5 сағат бұрын
Jake Wujastyk: S&P 500 and ES_F trade within last Thursday's range for a full week
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 ж. 04 жел.
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com